Nucleic Acid Nanomedicines in Phase II/III Clinical Trials: Translation of Nucleic Acid Therapies for Reprogramming Cells

What is it about?

The application of nanotechnology to medicine—Nanomedicine—offers an unprecedented opportunity to improve patient outcomes. This integrated review of emerging clinical successes and failures in Phase II/III clinical trials provides insight into how best to design new technologies for the delivery of nucleic acid therapies.

Featured Image